To Study the Occurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus.

Authors

  • Siddharth Arya Post Graduate Student, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre Author
  • Jigar M Haria Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre Author
  • Amit Mishra Assistant Professor, Department of Medicine, Teerthanker Mahaveer Medical College & Research Centre. Author

Keywords:

NAFLD, Diabetes, Fibroscan, LSM, Fibrosis

Abstract

Background: Macrovascular and Microvascular complications are well evaluated in DM but NAFLD is the most neglected and unevaluated  complication among DM.Fibroscan is the non-invasive method for assessing liver fibrosis which has high reproducibility and  accuracySubjects and Methods: It was a Case Control study. Fibrosis was assessed by fibroscan and was then quantified. Results: In our  study there was a significant difference seen among the different grades of fibrosis among controls and cases (p=0.004). The mean fibrosis  score too was high among cases (13.498) as compared to controls (6.052). The overall prevalence of NAFLD (F2-F4) was found to be 50%  among cases as compared to 14% in controls.Conclusion: Diabetes has a significant etiological role in occurrence of NAFLD in population.  Fibroscan has a substantial role in screening and diagnosing diabetics for NAFLD and fibrosis, thus advocating its use is recommended to  prevent understudied and unrecognized complication of DM preventing mortality and morbidity. 

Downloads

Download data is not yet available.

References

1. Duseja A, Sharma B, Kumar A, Kapil S, Das A, Dhiman RK, et al. Nonalcoholic fatty liver in a developing country is responsible for

significant liver disease. Hepatology. 2010 Dec;52(6):2248–9. 2. Sasso M, Beaugrand M, deLedinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36:1825–35.

3. American Diabetes Association. Standards of medical care in diabetes-- 2014. Diabetes Care. 2014 Jan;37Suppl 1: S14-80.

4. Wong VW-S, Vergniol J, Wong GL-H, Foucher J, Chan HL-Y, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010 Feb;51(2):454–62.

5. Agarwal AK, Jain V, Singla S, Baruah BP, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India. 2011 Jun; 59:351–4.

6. Tomeno W, Yoneda M, Imajo K, Suzuki K, Ogawa Y, Shinohara Y, et al. Evaluation of the Liver Fibrosis Index calculated by using real-time tissue elastography for the non-invasive assessment of liver fibrosis in chronic liver diseases. Hepatol Res. 2013 Jul;43(7):735–42.

Published

2020-01-30

How to Cite

To Study the Occurrence of Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus . (2020). Academia Journal of Medicine, 2(2), 207-210. https://medjournal.co.in/index.php/ajm/article/view/199